We scan new podcasts and send you the top 5 insights daily.
The NLRP3 inflammasome acts as the absolute first signal driving sterile inflammation triggered by internal damage signals such as oxidized lipids and cholesterol crystals. Because it is exclusively stimulated by these damage cues rather than pathogens, selectively inhibiting NLRP3 shuts down persistent sterile inflammatory damage while preserving the immune system's normal ability to recognize and respond to viral, fungal, and bacterial infections.
Chronic inflammation is readily measured in circulation, but pathological destruction occurs directly inside organ tissues, arterial walls, heart muscle, and the brain. Early NLRP3 inhibitors failed because limited bioavailability and restricted tissue access prevented them from altering tissue-level inflammation. Meaningful disease modification requires molecules engineered with high volume of distribution that rapidly transit out of the bloodstream and penetrate affected tissues.
Humans evolved a robust inflammatory response to fight constant threats like infections. In today's relatively sterile world, this powerful system lacks its historical targets and can overreact to modern triggers, leading to the chronic low-level inflammation that is at the heart of many modern diseases.
The gut barrier is a single cell layer protecting your immune system. When it weakens (leaky gut), food particles and toxins cross over into the bloodstream, triggering a 24/7 immune response. This constant, low-level battle is the primary driver of chronic low-grade inflammation throughout the body.
Beyond visible symptoms in autoimmune disease, "hidden inflammation" is a pervasive, low-level state that can silently damage the body for years. This paradigm shift identifies it not just as a consequence of disease, but a fundamental driver of top killers like heart disease, cancer, and even aging itself.
Circulating biomarkers like hsCRP show general pathway engagement but cannot identify the specific node of inhibition or reflect local tissue inflammation status. Patients routinely exhibit normal systemic hsCRP despite suffering severe inflammation within the cardiac wall, brain, or liver on imaging. As development in sterile neuroinflammation and cardiology advances, drug developers must increasingly rely on imaging rather than blood tests for indication selection and pharmacodynamic proof.
Our immune systems evolved to mount robust inflammatory responses against acute threats like infections and traumas. In the modern world, which lacks these constant threats, this same sensitivity causes our bodies to overreact to environmental triggers. This evolutionary mismatch creates the chronic, low-level inflammation that drives modern diseases.
Dr. Will Bolsiewicz distinguishes between life-saving acute inflammation (fighting infection, healing injury) and detrimental chronic low-grade inflammation. The latter is a constant, damaging immune response likened to a “forever war” inside the body, which is at the root of many modern diseases.
The modern definition of sepsis is not "blood poisoning" but a dysregulated host response. The immune system's inflammatory reaction spirals out of control, causing organ damage long after the initial infection is gone. In fact, fewer than half of sepsis patients have a detectable infection in their bloodstream.
The immune system deploys powerful "weapons" to fight invaders. However, an over-activated response, triggered by proteins like C5a, can cause these weapons to harm the body's own organs and tissues, similar to the collateral damage from a dirty bomb.
A paradigm shift in medicine suggests that unseen, low-level inflammation is not merely a consequence of disease but a fundamental root cause. This "silent fire" is a common thread linking top killers like heart disease, cancer, diabetes, and even neurodegenerative disorders, preceding their development by years.